# Who are Zoetis Inc.'s customers? Who does Zoetis Inc. earn revenue from?
Canonical: https://valuechain.wiki/zoetis · Facet: customers · Updated: 2026-09-24T03:12:37.120538+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Zoetis Inc.'s confirmed revenue counterparties include Cencora, Inc. plus 1 undisclosed/aggregate relationship. Per the valuechain.wiki graph: 2 revenue edges, backed by 6 dated sources, 3 of them primary filings (as of 2026-09-24).

### BlackRock (high)  → /blackrock.md
- metric: Market share 9% · As of 2026-06-30 · BlackRock beneficial ownership of Zoetis
- note: BlackRock reported beneficial ownership of 37,660,315 Zoetis shares, or 9.0%, as of June 30, 2026. The filing states that the shares were held in the ordinary course rather than to influence control.
- [confirms] SEC EDGAR (EN, filing, published 2026-07-30) https://www.sec.gov/Archives/edgar/data/1555280/000201238326003137/xslSCHEDULE_13G_X02/primary_doc.xml: "Aggregate Amount Beneficially Owned: 37,660,315. Percent of class: 9.0%."

### 센코라 (mid)  → /cencora.md
- note: Cencora-owned MWI Animal Health distributes Zoetis products into the U.S. veterinary market. Zoetis disclosed that its largest U.S. veterinary distributor represented 16% of FY2025 revenue, but did not name that customer, so the 16% is not attributed to Cencora here.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-12) https://www.sec.gov/Archives/edgar/data/1555280/000155528026000011/zts-20251231.htm: "Sales to our largest customer, a U.S. veterinary distributor, represented approximately 16% of total revenue for 2025."
- [mentions] ChoiceStock US (KO, analysis, published 2025-09-17) https://www.choicestock.co.kr/stock/research_view/6571: "The analysis says companion-animal products generate 68% of Zoetis revenue and the United States is its largest market, supporting the importance of the U.S. veterinary distribution channel."
- [confirms] SEC EDGAR (EN, filing, published 2015-01-12) https://www.sec.gov/Archives/edgar/data/1323974/000110465915001992/a15-2249_3ex99d1.htm: "If you look at some of our largest vendors, the biggest would be Zoetis."
- [confirms] SEC EDGAR (EN, filing, published 2013-11-27) https://www.sec.gov/Archives/edgar/data/1323974/000132397413000039/mwiv-20130930x10k.htm: "In 2013, Pfizer completed the spin off its animal health business as Zoetis, which is now our largest vendor, measured by revenues."

### Covetrus (mid)
- note: Covetrus lists Zoetis livestock parasiticides, anti-infectives, vaccines and hormone products in its ordering catalog for veterinary customers. Transaction value by counterparty is not disclosed.
- [mentions] News1 Korea (KO, news, published 2026-05-01) https://v.daum.net/v/y1vi9PmjYb: "Simparica Trio is a Zoetis all-in-one parasiticide prescribed by veterinarians at animal hospitals, and Zoetis Korea also sells Librela and Solensia."
- [confirms] Covetrus (EN, ir, published 2020-03-01) https://northamerica.covetrus.com/docs/default-source/landing-pages/cov_20eqls95-covetrus-2020-livestock-preferred-product-guide-042120.pdf?sfvrsn=55026d73_2: "The Covetrus product guide lists multiple Zoetis products, including Dectomax, Valbazen, Liquamycin, Draxxin and Lutalyse, as orderable selections."

Reverse side: https://valuechain.wiki/zoetis/suppliers.md · Ripple: https://valuechain.wiki/zoetis/ripple.md

---
Full node: https://valuechain.wiki/zoetis.md · JSON: https://valuechain.wiki/zoetis.json